Canopy Growth is ready to launch its cannabis oil in Peru

As the cannabis markets in Latin America keep expanding at a rapid pace, offering new treatment possibilities to patients, many companies around the world are looking for investment opportunities. Now, the Canadian cannabis company Canopy Growth has signed an agreement, after the approval by the DIGEMID, with Peru for the commercialization of one of its new products, Yellow Oil.

Spectrum Therapeutics, the medical division of Canopy Growth, a Canadian cannabis firm renowned worldwide thanks to the quality of its products, announced that DIGEMID approved the Health Registration of Yellow Oil 20 mg/ml Oral Solution for its commercialization in Peru.

This is the first finished natural medical cannabis product, produced by a private company, to be marketed in the Latin American country, which serves as a milestone and will help in the development of the Peruvian cannabis market.

If you want to know more about cannabis, how the Canadian cannabis company Canopy Growth is expanding its business in Peru, how the launch of this new cannabis product will benefit the cannabis market in the country, and to find out the latest cannabis news, download the Hemp.im mobile application.

Canopy Growth bets on the Peruvian cannabis market for the commercialization of its products

Yellow Oil is the name of the cannabis oil, the first product of the company approved in Peru. The color yellow is part of what the company calls the color code – the Spectrum, where each color represents a category of products based on Tetrahydrocannabinol (THC) and Cannabidiol (CBD) content. Yellow represents Cannabidiol (CBD), which is the main cannabinoid found in this product. 

The Canadian cannabis company is also moving forward with the registration of Spectrum Blue, which contains balanced amounts of THC and CBD, and Spectrum Red, a predominantly Tetrahydrocannabinol (THC) product. This color categorization was designed specifically to facilitate discussions between physicians and patients, providing a clear differentiation between available products.

“This approval is a major step towards patient access to high-quality cannabinoid-based pharmaceuticals across the country. It is also an opportunity for the development of the medical cannabis market in Peru, which could bring many benefits to the country, in which we are investing since our arrival, more than a year ago,” said Luis Larrabure, Physician and Sales and Marketing Director of Spectrum Therapeutics in Peru.

“This shows the quality of regulation in Peru and the work of activists and regulators to advance to this point where patients can purchase the product in pharmacies,” the Peruvian specialist added.

Canopy Growth offers high-quality products to its customers in Peru 

The cannabis oils and soft capsules of Canopy Growth Spectrum Therapeutics Division have as their origin a certified and traceable production, according to the Sanitary Standards required worldwide. The products have Good Manufacturing Practices (GMP) certification of pharmaceutical grade and are subject to strict control from the genetics of the cannabis plants to consumption by the patient in need of this treatment. 

Thanks to these controls, patients and physicians can be confident that Spectrum Therapeutics’ products are standardized, whether in Canada, Europe or Latin America, allowing for consistency of treatment.

The Canopy Growth Spectrum Therapeutics Division was founded in Canada and operates throughout Europe, Latin America, and Australia, currently serving more than 100,000 patients with high-quality cannabis-based products. 

The company’s operations include the production and distribution of medical cannabis products, as well as education, training, and support for patients and health professionals and also pre-clinical and clinical research and development of cannabinoid-based drugs.

__

(Featured image by Sergei Akulich via Pexels)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Hemp.im, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in El Economista America, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Hemp.im assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Hemp.im is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.